Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient

Nature Clinical Practice Nephrology

Volumn 2, Issue 8, 2006, Pages 459-463

  Trimarchi, Hernán ^a,b,c   Lombi, Fernando ^b   Forrester, Mariano ^b   Elizondo, Cristina ^b   Sawinski, Deirdre ^d   Pereyra, Horacio ^b   Freixas, Emilio ^b  

^a Renal Section   (Argentina)

^b HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^c AMERICAN COLLEGE OF PHYSICIANS   (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

Bisphosphonates; Hemodialysis; Hypercalcemia; Multiple myeloma; Pamidronate

Indexed keywords

CALCIUM; DOXORUBICIN; FOLIC ACID; OMEPRAZOLE; PAMIDRONIC ACID; PREDNISONE; SEVELAMER; VINCRISTINE SULFATE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DISEASE COURSE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; KIDNEY BIOPSY; KIDNEY FAILURE; LABORATORY TEST; LIVER TOXICITY; MALE; MULTIPLE MYELOMA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGURIA; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SEIZURE; SEROLOGY; SHORT COURSE THERAPY; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; DIPHOSPHONATES; HUMANS; HYPERCALCEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RENAL DIALYSIS;

EID: 33746790664     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0248     Document Type: Article

References (15)

1. Barri YM et al. (1996) Hypercalcemia and electrolyte disturbances in malignancy. Hematol Oncol Clin North Am 10: 775-790
2. Pearce CJ et al. (1991) Hypercalcemia due to calcium binding by a polymeric IgA Kappa paraprotein. Ann Clin Biochem 28: 229-234
3. Ratcliffe WA et al. (1992) Role of assays for parathyroid-hormone-related protein in the investigation of hypercalcaemia. Lancet 339: 164-167
4. Strewler GJ (2000) The physiology of parathyroid hormone-related protein. N Engl J Med 342: 177-185
5. Rajkumar V and Kyle R (2005) Multiple myeloma: diagnosis and treatment. Mayo Clinic Proc 80: 1371-1382
6. Glass DA et al. (2003) A new insight into the formation of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2479-2480
7. Scheinman SJ et al. (1991) Hypercalcemia with excess serum 1,25 dihydroxyvitamin D in lymphomatoid granulomatosis/angiocentric lymphoma. Am J Med Sci 301: 178-181
8. Popovtzer M et al. (1992) Disorders of calcium, phosphorus, vitamin D, and parathyroid hormone activity. In Renal and Electrolyte Disorders, edn 4, 287-369 (Ed. Schrier R) Boston: Little, Brown and Company
9. Rodan GA and Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97: 2692-2696
10. Fleisch HA (1998) Bisphosphonates: mechanism of action. Endoc Rev 19: 80-100
11. Markowitz G et al. (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12: 1164-1172
12. Lu KC et al. (2003) Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 42: 1221-1227
13. Torregrosa JV et al. (2003) Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int 63 (Suppl): S88-S90
14. Major PP and Cook R (2002) Efficacy of bisphosphonates in the management of skeletal complications of bone metastasis and selection of clinical endpoints. Am J Clin Oncol 25 (Suppl 1): S10-S18
15. Lindberg J and Moe S (1999) Osteoporosis in endstate renal disease. Semin Nephrol 19: 115-122